Dominic P Williams
Overview
Explore the profile of Dominic P Williams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seal S, Williams D, Hosseini-Gerami L, Mahale M, Carpenter A, Spjuth O, et al.
bioRxiv
. 2024 Jun;
PMID: 38895462
Drug-induced liver injury (DILI) has been significant challenge in drug discovery, often leading to clinical trial failures and necessitating drug withdrawals. The existing suite of in vitro proxy-DILI assays is...
2.
OBrien K, McNally B, Sowton A, Murgia A, Armitage J, Thomas L, et al.
BMC Biol
. 2021 Dec;
19(1):265.
PMID: 34911556
Background: Tissue hypoxia is a key feature of several endemic hepatic diseases, including alcoholic and non-alcoholic fatty liver disease, and organ failure. Hypoxia imposes a severe metabolic challenge on the...
3.
Brecklinghaus T, Albrecht W, Kappenberg F, Duda J, Vartak N, Edlund K, et al.
Chem Biol Interact
. 2021 Oct;
351:109728.
PMID: 34717914
An in vitro/in silico method that determines the risk of human drug induced liver injury in relation to oral doses and blood concentrations of drugs was recently introduced. This method...
4.
Antoine D, Williams D, Kipar A, Laverty H, Park B
Mol Med
. 2020 Dec;
26(1):130.
PMID: 33380325
No abstract available.
5.
Antoine D, Jenkins R, Dear J, Williams D, McGill M, Sharpe M, et al.
J Hepatol
. 2020 Oct;
73(5):1297.
PMID: 33070867
No abstract available.
6.
Basharat A, Rollison H, Williams D, Ivanov D
Toxicol Appl Pharmacol
. 2020 Oct;
408:115279.
PMID: 33068618
High-throughput, automation-friendly and therapeutically-predictive assays are needed in early drug discovery in order to prioritise compounds and reduce the risk of new drugs causing Drug-Induced Liver Injury (DILI). We evaluated...
7.
Jolly C, Douglas O, Kamalian L, Jenkins R, Beckett A, Penman S, et al.
Toxicol Appl Pharmacol
. 2020 Jul;
403:115163.
PMID: 32730777
During its clinical development fialuridine caused liver toxicity and the death of five patients. This case remains relevant due to the continued development of mechanistically-related compounds against a back-drop of...
8.
Lazic S, Semenova E, Williams D
Sci Rep
. 2020 Apr;
10(1):6625.
PMID: 32313041
Regulatory authorities require animal toxicity tests for new chemical entities. Organ weight changes are accepted as a sensitive indicator of chemically induced organ damage, but can be difficult to interpret...
9.
Leedale J, Kyffin J, Harding A, Colley H, Murdoch C, Sharma P, et al.
Interface Focus
. 2020 Mar;
10(2):20190041.
PMID: 32194929
In early preclinical drug development, potential candidates are tested in the laboratory using isolated cells. These experiments traditionally involve cells cultured in a two-dimensional monolayer environment. However, cells cultured in...
10.
Bell C, Chouhan B, Andersson L, Andersson H, Dear J, Williams D, et al.
Arch Toxicol
. 2020 Mar;
94(4):1251-1263.
PMID: 32112222
In addition to hepatocytes, the liver comprises a host of specialised non-parenchymal cells which are important to consider in the development of in vitro models which are both physiologically and...